Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically Ill Patients

[Guest guest]

Yes- but weren't all the cases of fungemia in immunocompromised

(and hospitalized) people?

I thought this yeast was nonpathogenic in immunocompetant people.

Barb

> In France, Ultralevure (made of S. Boulardii) is routinely

prescribed by doctors to prevent abx related diarrhea.

>

> Nelly

>

> (...)

> "

> " This review confirms that the most important risk factor for S.

cerevisiae fungemia is the use of probiotics, " write Dr. Raoul

Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

Strasbourg, France in a related editorial.

>

> " This raises the question of the risk-benefit ratio of these agents

in critically ill or immunocompromised patients who are likely to

develop an infection after exposure to high amounts of a pathogen

with a low virulence. "

>

>

>

>

>

>

> To Print: Click your browser's PRINT button.

> NOTE: To view the article with Web enhancements, go to:

> http://www.medscape.com/viewarticle/505940

>

>

> --------------------------------------------------------------------

------

>

> Saccharomyces Cerevisiae May Cause Fungemia in Critically Ill

Patients

>

>

>

> NEW YORK (Reuters Health) Jun 03 - Treatment with the

probiotic Saccharomyces cerevisiae may lead to fungemia in

immunosuppressed or critically ill patients, investigators in Madrid

report.

>

> S. cerevisiae is commonly used as a probiotic for the

treatment of antibiotic-related diarrhea, Dr. Munoz from

Hospital General Universitario " Gregorio Maranon, " and colleagues

explain.

>

> They identified three patients with S. cerevisiae fungemia in

an intensive care unit and reviewed the literature to identify

similar cases. All three patients had been treated for Clostridium

difficile-associated diarrhea with Ultralevura, a formulation of S.

boulardii (a strain of S. cerevisiae), the authors report, and all

three died of various causes.

>

> The strains isolated from the three patients were identical

to the strains from the probiotic formulation, according to the

results in the June 1st issue of Clinical Infectious Diseases. No

further cases were detected after the discontinuation of Ultralevura

in the intensive care unit.

>

> Review of the literature identified 57 additional cases of S.

cerevisiae fungemia, the researchers note, and at least 31 patients

were receiving probiotics or potentially exposed to other patients

who were receiving probiotics.

>

> The mortality rate among the reported cases of S. cerevisiae

fungemia was 28%.

>

> " The extent of this review indicates that S. cerevisiae

should be considered as a well-established cause of nosocomially

acquired yeast infection, particularly in patients receiving

prophylaxis or treatment with the probiotic Ultralevura, which should

be considered a risk factor for nosocomial bloodstream infection in

patients with predisposing underlying conditions, " the authors

conclude.

>

> " Therapy for S. cerevisiae fungemia should rely on the

withdrawal of the probiotic preparation, if it was being given,

administration of an antifungal agent, and, as with other types of

fungemia, withdrawal of central venous catheters, " the researchers

advise.

>

> " Until more data are available, " the investigators

suggest, " the antifungal agent of choice seems to be amphotericin B. "

>

> " This review confirms that the most important risk factor for

S. cerevisiae fungemia is the use of probiotics, " write Dr. Raoul

Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

Strasbourg, France in a related editorial.

>

> " This raises the question of the risk-benefit ratio of these

agents in critically ill or immunocompromised patients who are likely

to develop an infection after exposure to high amounts of a pathogen

with a low virulence. "

>

> " S. boulardii should certainly be contraindicated for

patients of fragile health, as well as for patients with a central

venous catheter in place, " the editorialists conclude. " Whether this

probiotic still has a place in less severe situations needs to be

reassessed. "

>

> Clin Infect Dis 2005;40:1625-1637.

>

>

> --------------------------------------------------------------------

------

[Guest guest]

That's right but aren't some of us immunocompromised to some extent? And some of us are taking abx such long term as well as taking probiotics in the hope of preventing intestinal probs. Just wondered if we might also have to think about the possibility of some probiotics causing problems (hopefully not death)

Nelly

[infections] Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically Ill Patients

Yes- but weren't all the cases of fungemia in immunocompromised(and hospitalized) people?I thought this yeast was nonpathogenic in immunocompetant people.Barb> In France, Ultralevure (made of S. Boulardii) is routinely prescribed by doctors to prevent abx related diarrhea. > > Nelly> > (...)> "> "This review confirms that the most important risk factor for S. cerevisiae fungemia is the use of probiotics," write Dr. Raoul Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre, Strasbourg, France in a related editorial.> > "This raises the question of the risk-benefit ratio of these agents in critically ill or immunocompromised patients who are likely to develop an infection after exposure to high amounts of a pathogen with a low virulence."> > > > > > > To Print: Click your browser's PRINT button.> NOTE: To view the article with Web enhancements, go to:> http://www.medscape.com/viewarticle/505940 > > > --------------------------------------------------------------------------> > Saccharomyces Cerevisiae May Cause Fungemia in Critically Ill Patients> > > > NEW YORK (Reuters Health) Jun 03 - Treatment with the probiotic Saccharomyces cerevisiae may lead to fungemia in immunosuppressed or critically ill patients, investigators in Madrid report.> > S. cerevisiae is commonly used as a probiotic for the treatment of antibiotic-related diarrhea, Dr. Munoz from Hospital General Universitario "Gregorio Maranon," and colleagues explain.> > They identified three patients with S. cerevisiae fungemia in an intensive care unit and reviewed the literature to identify similar cases. All three patients had been treated for Clostridium difficile-associated diarrhea with Ultralevura, a formulation of S. boulardii (a strain of S. cerevisiae), the authors report, and all three died of various causes.> > The strains isolated from the three patients were identical to the strains from the probiotic formulation, according to the results in the June 1st issue of Clinical Infectious Diseases. No further cases were detected after the discontinuation of Ultralevura in the intensive care unit.> > Review of the literature identified 57 additional cases of S. cerevisiae fungemia, the researchers note, and at least 31 patients were receiving probiotics or potentially exposed to other patients who were receiving probiotics.> > The mortality rate among the reported cases of S. cerevisiae fungemia was 28%.> > "The extent of this review indicates that S. cerevisiae should be considered as a well-established cause of nosocomially acquired yeast infection, particularly in patients receiving prophylaxis or treatment with the probiotic Ultralevura, which should be considered a risk factor for nosocomial bloodstream infection in patients with predisposing underlying conditions," the authors conclude.> > "Therapy for S. cerevisiae fungemia should rely on the withdrawal of the probiotic preparation, if it was being given, administration of an antifungal agent, and, as with other types of fungemia, withdrawal of central venous catheters," the researchers advise.> > "Until more data are available," the investigators suggest, "the antifungal agent of choice seems to be amphotericin B."> > "This review confirms that the most important risk factor for S. cerevisiae fungemia is the use of probiotics," write Dr. Raoul Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre, Strasbourg, France in a related editorial.> > "This raises the question of the risk-benefit ratio of these agents in critically ill or immunocompromised patients who are likely to develop an infection after exposure to high amounts of a pathogen with a low virulence."> > "S. boulardii should certainly be contraindicated for patients of fragile health, as well as for patients with a central venous catheter in place," the editorialists conclude. "Whether this probiotic still has a place in less severe situations needs to be reassessed."> > Clin Infect Dis 2005;40:1625-1637.> > > --------------------------------------------------------------------------

[Guest guest]

Maybe J. can comment- I look to him as the Yeast expert.

Barb

> > In France, Ultralevure (made of S. Boulardii) is routinely

> prescribed by doctors to prevent abx related diarrhea.

> >

> > Nelly

> >

> > (...)

> > "

> > " This review confirms that the most important risk factor for

S.

> cerevisiae fungemia is the use of probiotics, " write Dr. Raoul

> Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> Strasbourg, France in a related editorial.

> >

> > " This raises the question of the risk-benefit ratio of these

agents

> in critically ill or immunocompromised patients who are likely to

> develop an infection after exposure to high amounts of a pathogen

> with a low virulence. "

> >

> >

> >

> >

> >

> >

> > To Print: Click your browser's PRINT button.

> > NOTE: To view the article with Web enhancements, go to:

> > http://www.medscape.com/viewarticle/505940

> >

> >

> > ----------------------------------------------------------------

----

> ------

> >

> > Saccharomyces Cerevisiae May Cause Fungemia in Critically

Ill

> Patients

> >

> >

> >

> > NEW YORK (Reuters Health) Jun 03 - Treatment with the

> probiotic Saccharomyces cerevisiae may lead to fungemia in

> immunosuppressed or critically ill patients, investigators in

Madrid

> report.

> >

> > S. cerevisiae is commonly used as a probiotic for the

> treatment of antibiotic-related diarrhea, Dr. Munoz from

> Hospital General Universitario " Gregorio Maranon, " and colleagues

> explain.

> >

> > They identified three patients with S. cerevisiae

fungemia in

> an intensive care unit and reviewed the literature to identify

> similar cases. All three patients had been treated for

Clostridium

> difficile-associated diarrhea with Ultralevura, a formulation of

S.

> boulardii (a strain of S. cerevisiae), the authors report, and

all

> three died of various causes.

> >

> > The strains isolated from the three patients were

identical

> to the strains from the probiotic formulation, according to the

> results in the June 1st issue of Clinical Infectious Diseases. No

> further cases were detected after the discontinuation of

Ultralevura

> in the intensive care unit.

> >

> > Review of the literature identified 57 additional cases

of S.

> cerevisiae fungemia, the researchers note, and at least 31

patients

> were receiving probiotics or potentially exposed to other

patients

> who were receiving probiotics.

> >

> > The mortality rate among the reported cases of S.

cerevisiae

> fungemia was 28%.

> >

> > " The extent of this review indicates that S. cerevisiae

> should be considered as a well-established cause of nosocomially

> acquired yeast infection, particularly in patients receiving

> prophylaxis or treatment with the probiotic Ultralevura, which

should

> be considered a risk factor for nosocomial bloodstream infection

in

> patients with predisposing underlying conditions, " the authors

> conclude.

> >

> > " Therapy for S. cerevisiae fungemia should rely on the

> withdrawal of the probiotic preparation, if it was being given,

> administration of an antifungal agent, and, as with other types

of

> fungemia, withdrawal of central venous catheters, " the

researchers

> advise.

> >

> > " Until more data are available, " the investigators

> suggest, " the antifungal agent of choice seems to be amphotericin

B. "

> >

> > " This review confirms that the most important risk factor

for

> S. cerevisiae fungemia is the use of probiotics, " write Dr. Raoul

> Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> Strasbourg, France in a related editorial.

> >

> > " This raises the question of the risk-benefit ratio of

these

> agents in critically ill or immunocompromised patients who are

likely

> to develop an infection after exposure to high amounts of a

pathogen

> with a low virulence. "

> >

> > " S. boulardii should certainly be contraindicated for

> patients of fragile health, as well as for patients with a

central

> venous catheter in place, " the editorialists conclude. " Whether

this

> probiotic still has a place in less severe situations needs to be

> reassessed. "

> >

> > Clin Infect Dis 2005;40:1625-1637.

> >

> >

> > ----------------------------------------------------------------

----

> ------

>

>

>

>

>

>

>

[Guest guest]

Very flattering Barb ,, But yes Nelly is right, probiotics can infect ...there have been reports of people who have taken massive amounts of Probiotics in the hope that the good bugs will crowd out the bad...they ended up with a resprititory infection from those very bugs, the infection was life threatening...A Japanese doctor wrote a few papers on the subject ..i've just spent 30mins on the Candida archives looking for them ..no good , doesn't look as if the archives stretch back far enough..I'll put a question on the board see if anyone has the info ..

-----Original Message-----From: infections [mailto:infections ]On Behalf Of Barb PeckSent: 15 June 2005 20:27infections Subject: [infections] Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically Ill PatientsMaybe J. can comment- I look to him as the Yeast expert.Barb> > In France, Ultralevure (made of S. Boulardii) is routinely > prescribed by doctors to prevent abx related diarrhea. > > > > Nelly> > > > (...)> > "> > "This review confirms that the most important risk factor for S. > cerevisiae fungemia is the use of probiotics," write Dr. Raoul > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre, > Strasbourg, France in a related editorial.> > > > "This raises the question of the risk-benefit ratio of these agents > in critically ill or immunocompromised patients who are likely to > develop an infection after exposure to high amounts of a pathogen > with a low virulence."> > > > > > > > > > > > > > To Print: Click your browser's PRINT button.> > NOTE: To view the article with Web enhancements, go to:> > http://www.medscape.com/viewarticle/505940 > > > > > > --------------------------------------------------------------------> ------> > > > Saccharomyces Cerevisiae May Cause Fungemia in Critically Ill > Patients> > > > > > > > NEW YORK (Reuters Health) Jun 03 - Treatment with the > probiotic Saccharomyces cerevisiae may lead to fungemia in > immunosuppressed or critically ill patients, investigators in Madrid > report.> > > > S. cerevisiae is commonly used as a probiotic for the > treatment of antibiotic-related diarrhea, Dr. Munoz from > Hospital General Universitario "Gregorio Maranon," and colleagues > explain.> > > > They identified three patients with S. cerevisiae fungemia in > an intensive care unit and reviewed the literature to identify > similar cases. All three patients had been treated for Clostridium > difficile-associated diarrhea with Ultralevura, a formulation of S. > boulardii (a strain of S. cerevisiae), the authors report, and all > three died of various causes.> > > > The strains isolated from the three patients were identical > to the strains from the probiotic formulation, according to the > results in the June 1st issue of Clinical Infectious Diseases. No > further cases were detected after the discontinuation of Ultralevura > in the intensive care unit.> > > > Review of the literature identified 57 additional cases of S. > cerevisiae fungemia, the researchers note, and at least 31 patients > were receiving probiotics or potentially exposed to other patients > who were receiving probiotics.> > > > The mortality rate among the reported cases of S. cerevisiae > fungemia was 28%.> > > > "The extent of this review indicates that S. cerevisiae > should be considered as a well-established cause of nosocomially > acquired yeast infection, particularly in patients receiving > prophylaxis or treatment with the probiotic Ultralevura, which should > be considered a risk factor for nosocomial bloodstream infection in > patients with predisposing underlying conditions," the authors > conclude.> > > > "Therapy for S. cerevisiae fungemia should rely on the > withdrawal of the probiotic preparation, if it was being given, > administration of an antifungal agent, and, as with other types of > fungemia, withdrawal of central venous catheters," the researchers > advise.> > > > "Until more data are available," the investigators > suggest, "the antifungal agent of choice seems to be amphotericin B."> > > > "This review confirms that the most important risk factor for > S. cerevisiae fungemia is the use of probiotics," write Dr. Raoul > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre, > Strasbourg, France in a related editorial.> > > > "This raises the question of the risk-benefit ratio of these > agents in critically ill or immunocompromised patients who are likely > to develop an infection after exposure to high amounts of a pathogen > with a low virulence."> > > > "S. boulardii should certainly be contraindicated for > patients of fragile health, as well as for patients with a central > venous catheter in place," the editorialists conclude. "Whether this > probiotic still has a place in less severe situations needs to be > reassessed."> > > > Clin Infect Dis 2005;40:1625-1637.> > > > > > --------------------------------------------------------------------> ------> > > > > > >

[Guest guest]

Hey. That's why I'm here- to learn.

This is interesting.

I guess the key is balance.

I knew that the gut bugs had to be balanced, and that an over growth

of even what's normally called a " good gut bug " could cause problems,

BUT I didn't know you could over dose a probiotic - and cause an

overgrowth...on the contrary- I thought probiotics were quite

ineffective.. i.e. not very many CFUs in products and poor viability

in the gut.

Barb

> > > In France, Ultralevure (made of S. Boulardii) is routinely

> > prescribed by doctors to prevent abx related diarrhea.

> > >

> > > Nelly

> > >

> > > (...)

> > > "

> > > " This review confirms that the most important risk factor

for

> S.

> > cerevisiae fungemia is the use of probiotics, " write Dr. Raoul

> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> > Strasbourg, France in a related editorial.

> > >

> > > " This raises the question of the risk-benefit ratio of these

> agents

> > in critically ill or immunocompromised patients who are

likely to

> > develop an infection after exposure to high amounts of a

pathogen

> > with a low virulence. "

> > >

> > >

> > >

> > >

> > >

> > >

> > > To Print: Click your browser's PRINT button.

> > > NOTE: To view the article with Web enhancements, go

to:

> > > http://www.medscape.com/viewarticle/505940

> > >

> > >

> > > ------------------------------------------------------------

----

> ----

> > ------

> > >

> > > Saccharomyces Cerevisiae May Cause Fungemia in

Critically

> Ill

> > Patients

> > >

> > >

> > >

> > > NEW YORK (Reuters Health) Jun 03 - Treatment with the

> > probiotic Saccharomyces cerevisiae may lead to fungemia in

> > immunosuppressed or critically ill patients, investigators in

> Madrid

> > report.

> > >

> > > S. cerevisiae is commonly used as a probiotic for the

> > treatment of antibiotic-related diarrhea, Dr. Munoz

from

> > Hospital General Universitario " Gregorio Maranon, " and

colleagues

> > explain.

> > >

> > > They identified three patients with S. cerevisiae

> fungemia in

> > an intensive care unit and reviewed the literature to identify

> > similar cases. All three patients had been treated for

> Clostridium

> > difficile-associated diarrhea with Ultralevura, a formulation

of

> S.

> > boulardii (a strain of S. cerevisiae), the authors report, and

> all

> > three died of various causes.

> > >

> > > The strains isolated from the three patients were

> identical

> > to the strains from the probiotic formulation, according to

the

> > results in the June 1st issue of Clinical Infectious

Diseases. No

> > further cases were detected after the discontinuation of

> Ultralevura

> > in the intensive care unit.

> > >

> > > Review of the literature identified 57 additional

cases

> of S.

> > cerevisiae fungemia, the researchers note, and at least 31

> patients

> > were receiving probiotics or potentially exposed to other

> patients

> > who were receiving probiotics.

> > >

> > > The mortality rate among the reported cases of S.

> cerevisiae

> > fungemia was 28%.

> > >

> > > " The extent of this review indicates that S.

cerevisiae

> > should be considered as a well-established cause of

nosocomially

> > acquired yeast infection, particularly in patients receiving

> > prophylaxis or treatment with the probiotic Ultralevura, which

> should

> > be considered a risk factor for nosocomial bloodstream

infection

> in

> > patients with predisposing underlying conditions, " the authors

> > conclude.

> > >

> > > " Therapy for S. cerevisiae fungemia should rely on the

> > withdrawal of the probiotic preparation, if it was being

given,

> > administration of an antifungal agent, and, as with other

types

> of

> > fungemia, withdrawal of central venous catheters, " the

> researchers

> > advise.

> > >

> > > " Until more data are available, " the investigators

> > suggest, " the antifungal agent of choice seems to be

amphotericin

> B. "

> > >

> > > " This review confirms that the most important risk

factor

> for

> > S. cerevisiae fungemia is the use of probiotics, " write Dr.

Raoul

> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> > Strasbourg, France in a related editorial.

> > >

> > > " This raises the question of the risk-benefit ratio of

> these

> > agents in critically ill or immunocompromised patients who are

> likely

> > to develop an infection after exposure to high amounts of a

> pathogen

> > with a low virulence. "

> > >

> > > " S. boulardii should certainly be contraindicated for

> > patients of fragile health, as well as for patients with a

> central

> > venous catheter in place, " the editorialists

conclude. " Whether

> this

> > probiotic still has a place in less severe situations needs

to be

> > reassessed. "

> > >

> > > Clin Infect Dis 2005;40:1625-1637.

> > >

> > >

> > > ------------------------------------------------------------

----

> ----

> > ------

> >

> >

> >

> >

> >

> >

> >

[Guest guest]

Don't forget Barb , even good gut probiotic bugs are invaders , we develop antibodies against them . without the recognition protein coat ...all probiotics are destined to become ineffective as resistance [antibodies] develops

-----Original Message-----From: infections [mailto:infections ]On Behalf Of Barb PeckSent: 15 June 2005 22:15infections Subject: [infections] Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically Ill PatientsHey. That's why I'm here- to learn.This is interesting.I guess the key is balance.I knew that the gut bugs had to be balanced, and that an over growthof even what's normally called a "good gut bug" could cause problems, BUT I didn't know you could over dose a probiotic - and cause an overgrowth...on the contrary- I thought probiotics were quite ineffective.. i.e. not very many CFUs in products and poor viability in the gut.Barb> > > In France, Ultralevure (made of S. Boulardii) is routinely> > prescribed by doctors to prevent abx related diarrhea.> > >> > > Nelly> > >> > > (...)> > > "> > > "This review confirms that the most important risk factor for> S.> > cerevisiae fungemia is the use of probiotics," write Dr. Raoul> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,> > Strasbourg, France in a related editorial.> > >> > > "This raises the question of the risk-benefit ratio of these> agents> > in critically ill or immunocompromised patients who are likely to> > develop an infection after exposure to high amounts of a pathogen> > with a low virulence."> > >> > >> > >> > >> > >> > >> > > To Print: Click your browser's PRINT button.> > > NOTE: To view the article with Web enhancements, go to:> > > http://www.medscape.com/viewarticle/505940> > >> > >> > > ----------------------------------------------------------------> ----> > ------> > >> > > Saccharomyces Cerevisiae May Cause Fungemia in Critically> Ill> > Patients> > >> > >> > >> > > NEW YORK (Reuters Health) Jun 03 - Treatment with the> > probiotic Saccharomyces cerevisiae may lead to fungemia in> > immunosuppressed or critically ill patients, investigators in> Madrid> > report.> > >> > > S. cerevisiae is commonly used as a probiotic for the> > treatment of antibiotic-related diarrhea, Dr. Munoz from> > Hospital General Universitario "Gregorio Maranon," and colleagues> > explain.> > >> > > They identified three patients with S. cerevisiae> fungemia in> > an intensive care unit and reviewed the literature to identify> > similar cases. All three patients had been treated for> Clostridium> > difficile-associated diarrhea with Ultralevura, a formulation of> S.> > boulardii (a strain of S. cerevisiae), the authors report, and> all> > three died of various causes.> > >> > > The strains isolated from the three patients were> identical> > to the strains from the probiotic formulation, according to the> > results in the June 1st issue of Clinical Infectious Diseases. No> > further cases were detected after the discontinuation of> Ultralevura> > in the intensive care unit.> > >> > > Review of the literature identified 57 additional cases> of S.> > cerevisiae fungemia, the researchers note, and at least 31> patients> > were receiving probiotics or potentially exposed to other> patients> > who were receiving probiotics.> > >> > > The mortality rate among the reported cases of S.> cerevisiae> > fungemia was 28%.> > >> > > "The extent of this review indicates that S. cerevisiae> > should be considered as a well-established cause of nosocomially> > acquired yeast infection, particularly in patients receiving> > prophylaxis or treatment with the probiotic Ultralevura, which> should> > be considered a risk factor for nosocomial bloodstream infection> in> > patients with predisposing underlying conditions," the authors> > conclude.> > >> > > "Therapy for S. cerevisiae fungemia should rely on the> > withdrawal of the probiotic preparation, if it was being given,> > administration of an antifungal agent, and, as with other types> of> > fungemia, withdrawal of central venous catheters," the> researchers> > advise.> > >> > > "Until more data are available," the investigators> > suggest, "the antifungal agent of choice seems to be amphotericin> B."> > >> > > "This review confirms that the most important risk factor> for> > S. cerevisiae fungemia is the use of probiotics," write Dr. Raoul> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,> > Strasbourg, France in a related editorial.> > >> > > "This raises the question of the risk-benefit ratio of> these> > agents in critically ill or immunocompromised patients who are> likely> > to develop an infection after exposure to high amounts of a> pathogen> > with a low virulence."> > >> > > "S. boulardii should certainly be contraindicated for> > patients of fragile health, as well as for patients with a> central> > venous catheter in place," the editorialists conclude. "Whether> this> > probiotic still has a place in less severe situations needs to be> > reassessed."> > >> > > Clin Infect Dis 2005;40:1625-1637.> > >> > >> > > ----------------------------------------------------------------> ----> > ------> >> >> >> >> >> >> >

[Guest guest]

There are also studies on how bacteria can exchange genetic material

with probiotics, turning the probiotics into a new enemy. Perhaps

this is the case with the fungi too?

penny

> > > In France, Ultralevure (made of S. Boulardii) is routinely

> > prescribed by doctors to prevent abx related diarrhea.

> > >

> > > Nelly

> > >

> > > (...)

> > > "

> > > " This review confirms that the most important risk factor

for

> S.

> > cerevisiae fungemia is the use of probiotics, " write Dr.

Raoul

> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> > Strasbourg, France in a related editorial.

> > >

> > > " This raises the question of the risk-benefit ratio of

these

> agents

> > in critically ill or immunocompromised patients who are

likely to

> > develop an infection after exposure to high amounts of a

pathogen

> > with a low virulence. "

> > >

> > >

> > >

> > >

> > >

> > >

> > > To Print: Click your browser's PRINT button.

> > > NOTE: To view the article with Web enhancements, go

to:

> > > http://www.medscape.com/viewarticle/505940

> > >

> > >

> > > -----------------------------------------------------------

-----

> ----

> > ------

> > >

> > > Saccharomyces Cerevisiae May Cause Fungemia in

Critically

> Ill

> > Patients

> > >

> > >

> > >

> > > NEW YORK (Reuters Health) Jun 03 - Treatment with the

> > probiotic Saccharomyces cerevisiae may lead to fungemia in

> > immunosuppressed or critically ill patients, investigators in

> Madrid

> > report.

> > >

> > > S. cerevisiae is commonly used as a probiotic for the

> > treatment of antibiotic-related diarrhea, Dr. Munoz

from

> > Hospital General Universitario " Gregorio Maranon, " and

colleagues

> > explain.

> > >

> > > They identified three patients with S. cerevisiae

> fungemia in

> > an intensive care unit and reviewed the literature to

identify

> > similar cases. All three patients had been treated for

> Clostridium

> > difficile-associated diarrhea with Ultralevura, a

formulation of

> S.

> > boulardii (a strain of S. cerevisiae), the authors report,

and

> all

> > three died of various causes.

> > >

> > > The strains isolated from the three patients were

> identical

> > to the strains from the probiotic formulation, according to

the

> > results in the June 1st issue of Clinical Infectious

Diseases. No

> > further cases were detected after the discontinuation of

> Ultralevura

> > in the intensive care unit.

> > >

> > > Review of the literature identified 57 additional

cases

> of S.

> > cerevisiae fungemia, the researchers note, and at least 31

> patients

> > were receiving probiotics or potentially exposed to other

> patients

> > who were receiving probiotics.

> > >

> > > The mortality rate among the reported cases of S.

> cerevisiae

> > fungemia was 28%.

> > >

> > > " The extent of this review indicates that S.

cerevisiae

> > should be considered as a well-established cause of

nosocomially

> > acquired yeast infection, particularly in patients receiving

> > prophylaxis or treatment with the probiotic Ultralevura,

which

> should

> > be considered a risk factor for nosocomial bloodstream

infection

> in

> > patients with predisposing underlying conditions, " the

authors

> > conclude.

> > >

> > > " Therapy for S. cerevisiae fungemia should rely on

the

> > withdrawal of the probiotic preparation, if it was being

given,

> > administration of an antifungal agent, and, as with other

types

> of

> > fungemia, withdrawal of central venous catheters, " the

> researchers

> > advise.

> > >

> > > " Until more data are available, " the investigators

> > suggest, " the antifungal agent of choice seems to be

amphotericin

> B. "

> > >

> > > " This review confirms that the most important risk

factor

> for

> > S. cerevisiae fungemia is the use of probiotics, " write Dr.

Raoul

> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,

> > Strasbourg, France in a related editorial.

> > >

> > > " This raises the question of the risk-benefit ratio

of

> these

> > agents in critically ill or immunocompromised patients who

are

> likely

> > to develop an infection after exposure to high amounts of a

> pathogen

> > with a low virulence. "

> > >

> > > " S. boulardii should certainly be contraindicated for

> > patients of fragile health, as well as for patients with a

> central

> > venous catheter in place, " the editorialists

conclude. " Whether

> this

> > probiotic still has a place in less severe situations needs

to be

> > reassessed. "

> > >

> > > Clin Infect Dis 2005;40:1625-1637.

> > >

> > >

> > > -----------------------------------------------------------

-----

> ----

> > ------

> >

> >

> >

> >

> >

> >

> >

[Guest guest]

That's a thought provoking fact there Penny...Yes it's been said that all bacteria swim in the same genetic pool ..on the face of it we have no chance ..bacteria that can swap genetic material to enable their survival & to proliferate ...Only it doesn't happen ..we ingest millions of bacteria every day some will be pathogenic [one in a thousand bacteria is pathogenic] Those microbes generally do not overwhelme our defences ..in fact most live happily with substantial amounts of pathogenic bacteria ..The reason that many succumb to bacteria we host & others do not must be the balance of our gut flora ...Restoring a healthy balance is a key factor in regaining health...How to achieve that is the question ..probiotics will not do it ..or at least not the probiotics you can buy...

-----Original Message-----From: infections [mailto:infections ]On Behalf Of penny Sent: 16 June 2005 03:32infections Subject: [infections] Re: Saccharomyces Cerevisiae (incl S Boulardii) May Cause Fungemia in Critically Ill PatientsThere are also studies on how bacteria can exchange genetic material with probiotics, turning the probiotics into a new enemy. Perhaps this is the case with the fungi too?penny> > > In France, Ultralevure (made of S. Boulardii) is routinely> > prescribed by doctors to prevent abx related diarrhea.> > >> > > Nelly> > >> > > (...)> > > "> > > "This review confirms that the most important risk factor for> S.> > cerevisiae fungemia is the use of probiotics," write Dr. Raoul> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,> > Strasbourg, France in a related editorial.> > >> > > "This raises the question of the risk-benefit ratio of these> agents> > in critically ill or immunocompromised patients who are likely to> > develop an infection after exposure to high amounts of a pathogen> > with a low virulence."> > >> > >> > >> > >> > >> > >> > > To Print: Click your browser's PRINT button.> > > NOTE: To view the article with Web enhancements, go to:> > > http://www.medscape.com/viewarticle/505940> > >> > >> > > ----------------------------------------------------------------> ----> > ------> > >> > > Saccharomyces Cerevisiae May Cause Fungemia in Critically> Ill> > Patients> > >> > >> > >> > > NEW YORK (Reuters Health) Jun 03 - Treatment with the> > probiotic Saccharomyces cerevisiae may lead to fungemia in> > immunosuppressed or critically ill patients, investigators in> Madrid> > report.> > >> > > S. cerevisiae is commonly used as a probiotic for the> > treatment of antibiotic-related diarrhea, Dr. Munoz from> > Hospital General Universitario "Gregorio Maranon," and colleagues> > explain.> > >> > > They identified three patients with S. cerevisiae> fungemia in> > an intensive care unit and reviewed the literature to identify> > similar cases. All three patients had been treated for> Clostridium> > difficile-associated diarrhea with Ultralevura, a formulation of> S.> > boulardii (a strain of S. cerevisiae), the authors report, and> all> > three died of various causes.> > >> > > The strains isolated from the three patients were> identical> > to the strains from the probiotic formulation, according to the> > results in the June 1st issue of Clinical Infectious Diseases. No> > further cases were detected after the discontinuation of> Ultralevura> > in the intensive care unit.> > >> > > Review of the literature identified 57 additional cases> of S.> > cerevisiae fungemia, the researchers note, and at least 31> patients> > were receiving probiotics or potentially exposed to other> patients> > who were receiving probiotics.> > >> > > The mortality rate among the reported cases of S.> cerevisiae> > fungemia was 28%.> > >> > > "The extent of this review indicates that S. cerevisiae> > should be considered as a well-established cause of nosocomially> > acquired yeast infection, particularly in patients receiving> > prophylaxis or treatment with the probiotic Ultralevura, which> should> > be considered a risk factor for nosocomial bloodstream infection> in> > patients with predisposing underlying conditions," the authors> > conclude.> > >> > > "Therapy for S. cerevisiae fungemia should rely on the> > withdrawal of the probiotic preparation, if it was being given,> > administration of an antifungal agent, and, as with other types> of> > fungemia, withdrawal of central venous catheters," the> researchers> > advise.> > >> > > "Until more data are available," the investigators> > suggest, "the antifungal agent of choice seems to be amphotericin> B."> > >> > > "This review confirms that the most important risk factor> for> > S. cerevisiae fungemia is the use of probiotics," write Dr. Raoul> > Herbrecht and Dr. Yasmine Nivoix from Hopital de Hautepierre,> > Strasbourg, France in a related editorial.> > >> > > "This raises the question of the risk-benefit ratio of> these> > agents in critically ill or immunocompromised patients who are> likely> > to develop an infection after exposure to high amounts of a> pathogen> > with a low virulence."> > >> > > "S. boulardii should certainly be contraindicated for> > patients of fragile health, as well as for patients with a> central> > venous catheter in place," the editorialists conclude. "Whether> this> > probiotic still has a place in less severe situations needs to be> > reassessed."> > >> > > Clin Infect Dis 2005;40:1625-1637.> > >> > >> > > ----------------------------------------------------------------> ----> > ------> >> >> >> >> >> >> >

[Guest guest]

Probiotics won't do it? Do you have a suggestion. I am

having a real problem with this. When I take the

antibiotics the yeast grows big time. When I stop the

antibiotics I get sick again. What to do.

Marie

--- Jaep <Jaep@...> wrote:

> That's a thought provoking fact there Penny...Yes

> it's been said that all

> bacteria swim in the same genetic pool ..on the face

> of it we have no chance

> ..bacteria that can swap genetic material to enable

> their survival & to

> proliferate ...Only it doesn't happen ..we ingest

> millions of bacteria

> every day some will be pathogenic [one in a thousand

> bacteria is pathogenic]

> Those microbes generally do not overwhelme our

> defences ..in fact most live

> happily with substantial amounts of pathogenic

> bacteria ..The reason that

> many succumb to bacteria we host & others do not

> must be the balance of our

> gut flora ...Restoring a healthy balance is a key

> factor in regaining

> health...How to achieve that is the question

> ..probiotics will not do it

> ..or at least not the probiotics you can buy...

> [infections] Re:

> Saccharomyces Cerevisiae (incl S

> Boulardii) May Cause Fungemia in Critically Ill

> Patients

>

>

> There are also studies on how bacteria can

> exchange genetic material

> with probiotics, turning the probiotics into a new

> enemy. Perhaps

> this is the case with the fungi too?

>

> penny

>

>

> > > > In France, Ultralevure (made of S.

> Boulardii) is routinely

> > > prescribed by doctors to prevent abx

> related diarrhea.

> > > >

> > > > Nelly

> > > >

> > > > (...)

> > > > "

> > > > " This review confirms that the most

> important risk factor

> for

> > S.

> > > cerevisiae fungemia is the use of

> probiotics, " write Dr.

> Raoul

> > > Herbrecht and Dr. Yasmine Nivoix from

> Hopital de Hautepierre,

> > > Strasbourg, France in a related editorial.

> > > >

> > > > " This raises the question of the

> risk-benefit ratio of

> these

> > agents

> > > in critically ill or immunocompromised

> patients who are

> likely to

> > > develop an infection after exposure to

> high amounts of a

> pathogen

> > > with a low virulence. "

> > > >

> > > >

> > > >

> > > >

> > > >

> > > >

> > > > To Print: Click your browser's

> PRINT button.

> > > > NOTE: To view the article with Web

> enhancements, go

> to:

> > > >

> http://www.medscape.com/viewarticle/505940

> > > >

> > > >

> > > >

>

-----------------------------------------------------------

> -----

> > ----

> > > ------

> > > >

> > > > Saccharomyces Cerevisiae May Cause

> Fungemia in

> Critically

> > Ill

> > > Patients

> > > >

> > > >

> > > >

> > > > NEW YORK (Reuters Health) Jun 03 -

> Treatment with the

> > > probiotic Saccharomyces cerevisiae may

> lead to fungemia in

> > > immunosuppressed or critically ill

> patients,

=== message truncated ===

__________________________________

Stay connected, organized, and protected. Take the tour:

http://tour.mail./mailtour.html

[Guest guest]

Have you tried enzymes and long chain fatty acids??

My IgA titer for Candida was 2.5 (normal is < 0.8) after

lyme therapy. IgA and IgM were not out of range, so my DOc and I

figured it was still contained in my mucosal membranes.

It took 8 months- but Candex and Lauric acid (Lauricidin or Coconut

oil) brought me back to normal.

Barb

> > > > > In France, Ultralevure (made of S.

> > Boulardii) is routinely

> > > > prescribed by doctors to prevent abx

> > related diarrhea.

> > > > >

> > > > > Nelly

> > > > >

> > > > > (...)

> > > > > "

> > > > > " This review confirms that the most

> > important risk factor

> > for

> > > S.

> > > > cerevisiae fungemia is the use of

> > probiotics, " write Dr.

> > Raoul

> > > > Herbrecht and Dr. Yasmine Nivoix from

> > Hopital de Hautepierre,

> > > > Strasbourg, France in a related editorial.

> > > > >

> > > > > " This raises the question of the

> > risk-benefit ratio of

> > these

> > > agents

> > > > in critically ill or immunocompromised

> > patients who are

> > likely to

> > > > develop an infection after exposure to

> > high amounts of a

> > pathogen

> > > > with a low virulence. "

> > > > >

> > > > >

> > > > >

> > > > >

> > > > >

> > > > >

> > > > > To Print: Click your browser's

> > PRINT button.

> > > > > NOTE: To view the article with Web

> > enhancements, go

> > to:

> > > > >

> > http://www.medscape.com/viewarticle/505940

> > > > >

> > > > >

> > > > >

> >

> -----------------------------------------------------------

> > -----

> > > ----

> > > > ------

> > > > >

> > > > > Saccharomyces Cerevisiae May Cause

> > Fungemia in

> > Critically

> > > Ill

> > > > Patients

> > > > >

> > > > >

> > > > >

> > > > > NEW YORK (Reuters Health) Jun 03 -

> > Treatment with the

> > > > probiotic Saccharomyces cerevisiae may

> > lead to fungemia in

> > > > immunosuppressed or critically ill

> > patients,

> === message truncated ===

>

>

>

>

> __________________________________

>

> Stay connected, organized, and protected. Take the tour:

> http://tour.mail./mailtour.html

[Guest guest]

I have heard of Lauric Acid but not Candex. Can you

give me a source? I need all the help I can get.

Thanks, Marie

--- Barb Peck <egroups1bp@...> wrote:

> Have you tried enzymes and long chain fatty acids??

>

> My IgA titer for Candida was 2.5 (normal is < 0.8)

> after

> lyme therapy. IgA and IgM were not out of range, so

> my DOc and I

> figured it was still contained in my mucosal

> membranes.

>

> It took 8 months- but Candex and Lauric acid

> (Lauricidin or Coconut

> oil) brought me back to normal.

>

> Barb

>

>

>

>

> > > > > > In France, Ultralevure (made of S.

> > > Boulardii) is routinely

> > > > > prescribed by doctors to prevent abx

> > > related diarrhea.

> > > > > >

>

=== message truncated ===

__________________________________________________

[Guest guest]

U thought it was short chain fatty acids?

Like caprilic acid??

Im on ALA at the mo and it seems to be helping, but im dealing with

some thrombrosis shit in the head.

bleu

On 24 Jun 2005, at 21:39, Marie Mayberry wrote:

> I have heard of Lauric Acid but not Candex. Can you

> give me a source? I need all the help I can get.

> Thanks, Marie

>

> --- Barb Peck <egroups1bp@...> wrote:

>

> > Have you tried enzymes and long chain fatty acids??

> >

> > My IgA titer for Candida was 2.5 (normal is < 0.8)

> > after

> > lyme therapy.  IgA and IgM were not out of range, so

> > my DOc and I

> > figured it was still contained in my mucosal

> > membranes.

> >

> > It took 8 months- but Candex and Lauric acid

> > (Lauricidin or Coconut

> > oil) brought me back to normal.

> >

> > Barb

> >

> >

> >

> >

> > > >   >   >   > In France, Ultralevure (made of S.

> > > > Boulardii) is routinely

> > > >   >   >   prescribed by doctors to prevent abx

> > > > related diarrhea.

> > > >   >   >   >

> >

> === message truncated ===

>

>

> __________________________________________________

>